Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,833.50p on 18-12-2025 at 06:00:05
Change 0.00p 0%
Buy 1,850.00p
Sell 1,800.00p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Buy 100,000.00 at 1,832.813p
Day's Volume: 0
Last Close: 1,833.50p
Open: 0.00p
ISIN: GB00BN7SWP63
Day's Range 0.00p - 0.00p
52wk Range: 1,242.50p - 1,853.50p
Market Capitalisation: £73.98b
VWAP: 0.00p
Shares in Issue: 4.03b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 100,000 1,832.813p SI Trade
 16:51:54 - 17-Dec-25
Sell* 2,580 1,833.50p Automatic Execution
 16:39:21 - 17-Dec-25
Sell* 7,740 1,833.50p Automatic Execution
 16:39:21 - 17-Dec-25
Sell* 5,160 1,833.50p Automatic Execution
 16:39:20 - 17-Dec-25
Buy* 3,469 1,833.50p Automatic Execution
 16:37:34 - 17-Dec-25
Buy* 13,431 1,833.50p Automatic Execution
 16:37:34 - 17-Dec-25
Buy* 19,447 1,833.50p Automatic Execution
 16:37:34 - 17-Dec-25
Buy* 9,474 1,833.50p SI Trade
 16:35:09 - 17-Dec-25
Buy* 723 1,833.50p SI Trade
 16:35:09 - 17-Dec-25
Buy* 1,288 1,833.50p SI Trade
 16:35:09 - 17-Dec-25
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
18th Dec 2025 (Thu) 1,833.50 1,833.50 1,833.50 1,833.50 0
17th Dec 2025 (Wed) 1,826.00 1,850.50 1,823.50 1,833.50 10,914,252
16th Dec 2025 (Tue) 1,844.50 1,850.00 1,816.00 1,819.50 7,636,767
15th Dec 2025 (Mon) 1,819.00 1,838.50 1,810.00 1,833.50 10,789,160
12th Dec 2025 (Fri) 1,816.50 1,837.50 1,815.00 1,824.50 11,917,084
11th Dec 2025 (Thu) 1,805.00 1,821.00 1,792.50 1,821.00 8,075,205
10th Dec 2025 (Wed) 1,780.00 1,807.50 1,769.50 1,803.50 6,940,061
9th Dec 2025 (Tue) 1,821.00 1,822.50 1,780.00 1,783.00 8,159,545
8th Dec 2025 (Mon) 1,812.50 1,822.00 1,802.50 1,820.50 5,964,130
5th Dec 2025 (Fri) 1,826.50 1,833.00 1,796.00 1,805.00 4,275,273
4th Dec 2025 (Thu) 1,827.50 1,853.50 1,818.50 1,826.00 9,013,434
3rd Dec 2025 (Wed) 1,835.00 1,848.50 1,830.00 1,833.00 9,068,561
2nd Dec 2025 (Tue) 1,786.50 1,828.00 1,781.50 1,819.00 8,473,958
1st Dec 2025 (Mon) 1,790.50 1,823.00 1,783.00 1,800.00 12,290,851
28th Nov 2025 (Fri) 1,809.50 1,809.50 1,785.50 1,791.00 4,299,102
27th Nov 2025 (Thu) 1,805.00 1,812.00 1,795.50 1,802.00 8,413,515
26th Nov 2025 (Wed) 1,798.50 1,820.00 1,794.50 1,814.00 10,807,305
25th Nov 2025 (Tue) 1,789.50 1,809.00 1,778.00 1,795.00 9,012,395
24th Nov 2025 (Mon) 1,793.50 1,794.00 1,774.50 1,794.00 22,545,525
21st Nov 2025 (Fri) 1,756.50 1,788.00 1,753.00 1,788.00 8,671,411
20th Nov 2025 (Thu) 1,778.00 1,783.00 1,755.00 1,760.50 8,550,402
19th Nov 2025 (Wed) 1,784.00 1,788.00 1,772.50 1,772.50 8,032,928
18th Nov 2025 (Tue) 1,799.00 1,804.50 1,771.00 1,787.00 10,582,497
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
17th Dec 2025 7:00 am RNS Exdensur (depemokimab ulla) approved by US FDA
17th Dec 2025 7:00 am RNS Transaction in Own Shares
16th Dec 2025 7:00 am RNS Exdensur (depemokimab) UK MHRA approval
16th Dec 2025 7:00 am RNS Transaction in Own Shares
15th Dec 2025 7:00 am RNS Transaction in Own Shares
12th Dec 2025 1:50 pm RNS Nucala receives positive CHMP opinion for COPD
12th Dec 2025 1:41 pm RNS Depemokimab receives positive CHMP opinion
12th Dec 2025 7:00 am RNS Positive CHMP opinion on Arexvy for all adults 18+
12th Dec 2025 7:00 am RNS Transaction in Own Shares
11th Dec 2025 5:54 pm RNS Blujepa approved in US for gonorrhoea indication
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

GSK secures US FDA approval for "innovative" severe asthma treatment

17th Dec 2025 09:50

(Alliance News) - GSK PLC on Wednesday said its Exdensur treatment, depemokimab, for severe asthma has been approved by the US Food & Drug Administration. Read More

GSK receives UK marketing approval for asthma treatment Exdensur

15th Dec 2025 20:48

(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. Read More

GSK hails positive opinion by EU's CHMP on depemokimab and Nucala

12th Dec 2025 14:23

(Alliance News) - GSK PLC on Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of depemokimab in two indications. Read More

GSK's Arexvy on track for wider age range approval in Europe

12th Dec 2025 09:22

(Alliance News) - GSK PLC on Friday said European regulators have recommended broadening the indication for its Arexvy vaccine to all adults aged 18 and older. Read More

LONDON BRIEFING: FTSE 100 to rise, UK GDP down, trade deficit spikes

12th Dec 2025 07:43

(Alliance News) - Stocks were called to open higher in London on Friday, as the Office for National Statistics reported that the UK economy unexpectedly shrank in October. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value9,774.32
Change0.00

Login to your account

Forgot Password?

Not Registered